CDMO News
GC Cell Signs CDMO Deal with Dewcell for Stem Cell-Derived Artificial Platelets
GC Cell has announced a CDMO agreement with Dewcell, a Korean biotech firm developing stem cell-derived artificial platelets. The partnership will focus on the production and clinical readiness of Dewcell’s lead candidate, DCB-101 (en-aPLT), aimed at addressing chronic blood supply
10 July 2025